Approval of new Alzheimer's drug in Canada called historic

The drug, Lecanemab, could be available to some Ottawa patients within months. But it is not yet covered by provincial drug plans.

Article content

The approval of a new drug that can slow the progress of Alzheimer ’s disease is being hailed as a historic moment in the treatment of a disease projected to affect one million Canadians by 2030. Article content

The drug, lecanemab, was approved by Health Canada this week. It is the first treatment available in Canada to focus on the underlying condition and not its symptoms. The treatment could be available to some Ottawa patients with mild cognitive impairment within a matter of months. Article content Article content

But amid excitement about long-awaited progress in the treatment of Alzheimer’s disease, there is some caution. Lecan